Clinical Trial Update: A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL [Phase 1, Phase 2]

View source ↗

Summary

An early-phase Phase I/II trial evaluating TRS005 in combination with T-CHP (cyclophosphamide, doxorubicin, prednisone) for previously untreated CD20-positive d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• TRS005 (TRS005)

Snippet

Sponsor: Zhejiang Teruisi Pharmaceutical Inc. | Conditions: Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING